Dishman Pharmaceuticals and Chemicals on June 22, 2004, announced closure of its estimated $22 million debt issue programme. This issue was structured and syndicated by Rabo India Finance, with participation from multilateral agencies such as the FMO of the Netherlands and DEG of Germany. This deal is structured in the form of a future flow securitisation of the receivables from its long-term contract manufacturing agreement with Solvay Pharmaceuticals BV, the Netherlands.
